Publicaciones en las que colabora con O. Pfaar (20)

2023

  1. Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 11, pp. 2851-2874

  2. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1169-1203

2021

  1. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy

    Clinical and Translational Allergy, Vol. 11, Núm. 4

  2. COVID-19 pandemic and allergen immunotherapy—an EAACI survey

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 11, pp. 3504-3516

  3. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 3, pp. 648-676

  4. EAACI Biologicals Guidelines—Recommendations for severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 14-44

  5. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 8, pp. 2337-2353

  6. Management of anaphylaxis due to COVID-19 vaccines in the elderly

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 10, pp. 2952-2964

  7. One Hundred Ten Years of Allergen Immunotherapy: A Broad Look Into the Future

    The journal of allergy and clinical immunology. In practice, Vol. 9, Núm. 5, pp. 1791-1803

2020

  1. A compendium answering 150 questions on COVID-19 and SARS-CoV-2

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 10, pp. 2503-2541

  2. Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie

    Allergologie, Vol. 43, Núm. 7, pp. 255-271

  3. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 11, pp. 2764-2774

  4. In-vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan—An EAACI position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 9, pp. 2161-2169

  5. State-of-the-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI)

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 4, pp. 746-760

2019

  1. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 74, Núm. 5, pp. 855-873

  2. Prioritizing research challenges and funding for allergy and asthma and the need for translational research—The European Strategic Forum on Allergic Diseases

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 74, Núm. 11, pp. 2064-2076

2017

  1. Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 72, Núm. 12, pp. 1825-1848